Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaViktoras Frismantas, Jean‐Pierre Bourquin, Julie Irving et al.|Blood|2017Cited by 263
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 TrialPeter Bader, Christina Peters, Arend von Stackelberg et al.|Journal of Clinical Oncology|2015Cited by 132
Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALLScott McComb, Beat Bornhäuser, Júlia Aguadé-Gorgorió et al.|Science Translational Medicine|2016Cited by 119
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Andrea Jarisch, Claudia Rössig et al.|Blood Advances|2023Cited by 57
Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemiaBarbara Meissner, Martin Stanulla, Thies Bartram et al.|Human Molecular Genetics|2013Cited by 18